Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Aims For Greater Role In Pharma Business Continuity Planning

Executive Summary

Legislative proposals described in the US FDA’s FY 2020 budget request justification document would give the agency more authority to oversee business continuity planning at pharmaceutical companies with the idea of preventing shortages of essential drugs.

You may also be interested in...



Coronavirus Legislation On Pharma Supply Chain Aims to Repatriate Manufacturing

But bipartisan bill only mandates a study on how the US could restore domestic manufacturing, reduce dependence on China.

A Rebuke To Pharma Globalization? Coronavirus Shows Value Of Regional Supply Chain Redundancy

As virus impedes China’s API production and spreads to other global manufacturing centers, need for robust supply chain alternatives becomes clear.

Coronavirus Not Impacting Rx Manufacturing Supply Chain – Yet

US FDA’s drug shortage team continues to check in with sponsors, but so far the infections and quarantines have not impacted drug production.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel